NFKB1 and sarcoma: Although it has been recently shown that IKKα can activate the canonical pathway as a compensatory mechanism in the absence of IKKβ [17], our data demonstrates that in sarcomas both catalytic subunits mutually contribute to the activation of NF-κB in response to doxorubicin.